TBI Identification and Monitoring Through Retinal Scanning

项目摘要/摘要 Rebion生产了一款便携设备-在NS117553的支持下-显示了用作 一种可以识别由于脑外伤造成的功能损害的工具。该设备使用视网膜扫描来测量 视网膜和大脑的视觉通路之间的中断。这项工作的长期愿景是 开发一种工具，用于在受伤时和受伤期间对受伤情况进行功能评估 恢复，并与目前可用的基于血液的生物标志物配对，以提供全面的报告 为患者和提供者服务。与眼睛跟踪或任何其他可用的眼睛技术不同，该设备的方法是 以评估视网膜和大脑之间的信号质量。对功能和整体进行准确监控 从TBI中恢复是医疗体系中服务不足的问题，Rebion正寻求帮助解决这些问题。 创伤性脑损伤是导致未成年人长期残疾和死亡的主要原因。 45岁。美国每年报告的脑损伤病例超过250万例，约有300-500万人 患有与脑外伤相关的残疾。大约75%的被诊断为脑损伤的患者被归类为脑损伤，这可以 很难诊断，因为病史往往不完整，症状没有特异性，与广泛的 一系列神经精神障碍。尽管大多数mTBI患者完全康复，但多达20%的患者 不要这样做。这些都是Rebion最终专注于帮助的患者。经历过的个人 多发性mTBI持续出现损伤后症状和长期并发症的风险增加，包括 严重后遗症，如慢性创伤性脑病(CTE)。简单的干预措施，如移除 来自危险环境的患者可以通过让大脑有时间痊愈和 防止进一步的伤害。 正在请求提供支持，以支持一项人体研究，该研究将把Rebion设备与 对怀疑患有脑外伤的参与者进行了一系列临床测试-血液生物标记物和神经认知评估。 到目前为止收集的试验数据表明，这种快速、非侵入性的方法在 病人在脑外伤中的旅程。

Project Summary/Abstract Rebion has produced a portable device – with support from NS117553 – that shows potential for serving as a tool that can identify functional impairment as a result of TBI. The device uses a retinal scan to measure disruptions between the retina and the visual pathway of the brain. The long-term vision of this work is to develop a tool that can serve as a functional assessment of injury at the time of injury, as well as during recovery, and to be paired with currently-available blood-based biomarkers to provide a comprehensive report for patients and providers. The device’s approach, unlike eye-tracking or any other available eye technology, is to assess the quality of signals between the retina and the brain. Accurate monitoring of function and overall recovery from TBI are underserved problems in the healthcare system that Rebion is seeking to help solve. TBI (traumatic brain injury) is the leading cause of long-term disability and death for individuals under the age of 45. Over 2.5 million cases of TBI are reported each year in the United States, with ~3-5 million individuals living with TBI-related disabilities. About 75% of patients diagnosed with TBI are classified as mTBI, which can be difficult to diagnose, as history is often incomplete and symptoms are nonspecific and overlap with a broad range of neuropsychiatric disorders. Although most patients with mTBI make a full recovery, as many as 20% do not. These are the patients that Rebion is ultimately focused on helping. Individuals who experience multiple mTBI are at increased risk of persistent post-injury symptoms and long-term complications, including serious sequelae such as chronic traumatic encephalopathy (CTE). Simple interventions such as removing the patient from risky environments may prevent these complications by allowing time for the brain to heal and preventing further injury. Grant support is being requested to support a human-subject study which will compare the Rebion device to a battery of clinical tests – blood biomarkers and neurocognitive assessments – in participants suspected of TBI. Pilot data collected to-date shows promise that this rapid, non-invasive method can serve a useful purpose in the patient’s journey through TBI.